guest ::
| Home > Publications database > Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort. > print |
| Home > Publications database > Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort. > print |
| 001 | 180148 | ||
| 005 | 20240229145608.0 | ||
| 024 | 7 | _ | |a 10.1007/s10143-022-01815-2 |2 doi |
| 024 | 7 | _ | |a pmid:35633420 |2 pmid |
| 024 | 7 | _ | |a 0344-5607 |2 ISSN |
| 024 | 7 | _ | |a 1437-2320 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2022-01135 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kong, Lu |b 0 |
| 245 | _ | _ | |a Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort. |
| 260 | _ | _ | |a New York |c 2022 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1662121851_13424 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2022 Aug;45(4):2961-2973 |
| 520 | _ | _ | |a Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making.Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Brainstem cavernous malformation |2 Other |
| 650 | _ | 7 | |a Cavernoma |2 Other |
| 650 | _ | 7 | |a Cerebral cavernous malformation |2 Other |
| 650 | _ | 7 | |a Hemorrhage risk |2 Other |
| 650 | _ | 7 | |a Natural history |2 Other |
| 700 | 1 | _ | |a Ma, Xiu-Jian |0 P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3 |b 1 |u dkfz |
| 700 | 1 | _ | |a Xu, Xiao-Ying |b 2 |
| 700 | 1 | _ | |a Liu, Pan-Pan |b 3 |
| 700 | 1 | _ | |a Wu, Ze-Yu |b 4 |
| 700 | 1 | _ | |a Zhang, Li-Wei |b 5 |
| 700 | 1 | _ | |a Zhang, Jun-Ting |b 6 |
| 700 | 1 | _ | |a Wu, Zhen |b 7 |
| 700 | 1 | _ | |a Wang, Liang |b 8 |
| 700 | 1 | _ | |a Li, Da |0 0000-0003-0629-0742 |b 9 |
| 773 | _ | _ | |a 10.1007/s10143-022-01815-2 |0 PERI:(DE-600)1474861-7 |n 4 |p 2961-2973 |t Neurosurgical review |v 45 |y 2022 |x 0344-5607 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:180148 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-26 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-26 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-08 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROSURG REV : 2021 |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-08 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-08 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-08 |
| 920 | 1 | _ | |0 I:(DE-He78)A240-20160331 |k A240 |l A240 Molekulare Neurogenetik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A240-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|